Skip to main content

Table 1 Patient characteristics and treatments

From: Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

Mean age

58.4 (range 44–77)

   

N = 25

%

Sex

Male

17

68

 

Female

8

32

TNM Stage

T

X

4

16

  

0

0

0

  

1

4

10

  

2

7

28

  

3

7

28

  

4

3

12

 

N

X

0

0

  

0

18

72

  

1

0

0

  

2

7

28

 

M

0

0

0

  

1

25

100

Histology

Clear cell

21

84

 
 

Papillary

4

16

 

Sites of disease

Lung

16

64

 
 

Lymph node

9

36

 
 

Soft tissue

7

28

 
 

Bone

6

24

 
 

Kidney

5

20

 
 

Liver

5

20

 
 

Pancreas

2

8

 
 

Adrenal

1

4

 

Prior Therapy

Nephrectomy

23

92

 
 

Chemotherapy

8

32

 
 

Immunotherapy

10

40

 
 

Radiation therapy

2

8

 
 

Cryoablation

1

4

 
 

Laser ablation

1

4

 

Treatment Characteristics

Vaccination

≤ 2

3

12

 
 

3–5

14

56

 
 

≥ 6

8

32

 

No. of IL-2 Cycles

1

4

16

 
 

2

9

36

 
 

3

0

0

 
 

4

9

36

 
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us